A Clinical Case of Palliative Care during the Progression of a Patient with Advanced Lung Cancer Undergoing Gefitinib Therapy and Subsequent Transition to Osimertinib: The Role of Palliative Care in Oncology

The article presents a clinical case of a 65-year-old female patient with stage IV adenocarcinoma of the right lung harboring an EGFR-mutated (L858R). The key feature of this case is the sequential modification of targeted therapy: initial stabilization with osimertinib, transient progression with associate complications during Gefitinib therapy, and subsequent restoration of disease control following reintroduction of osimertinib. A comprehensive palliative care approach is described in detail, including repeated thoracenteses, long-term pleural drainage, and supportive therapy aimed at symptom control and maintenance of the patient’s functional status. This case highlights the importance of integrating palliative interventions into oncological practice from the early stages of treatment, as well as the advantages of original targeted agents in overcoming tumor resistance.

1. Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629-640. PMID: 27959700. PMCID: PMC6762027. https://doi.org/10.1056/nejmoa1612674

2. Goss G, Tsai CM, Shepherd FA, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643-1652. PMID: 27751847. https://doi.org/10.1016/s1470-2045(16)30508-3

3. Лактионов К.К., Артамонова Е.В., Бредер В.В., Горбунова В.А., Демидова И. А., Деньгина Н.В. и соавт. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого. Практические рекомендации RUSSCO, часть 1. Злокачественные опухоли, 2023 (том 13), #3s2, стр. 42–65. DOI: 10.18027/2224-5057-2023-13-3s2-1-42-65. https://rosoncoweb.ru/standarts/RUSSCO/2023/2023-02.pdf

4. Weijie Ma, Jay Gong, Jidong Shan, Debbie Lewis, Wenwu Xiao, Elizabeth H. Moore, Yanhong Zhang, Jamie Hung, Nicole Z. Mans, Sixi Wei, Jenna Welborn, Nicholas S. Stollenwerk, Kit S. Lam, and Tianhong. Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFRT790M Mutations. JCO Precis Oncol 2, 1-7(2018). https://ascopubs.org/doi/10.1200/PO.18.00076

5. Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018;378(2):113-125. PMID: 29151359. https://doi.org/10.1056/nejmoa1713137

6. Gillespie L, Raftery AM. Nutrition in palliative and end-of-life care. Br J Community Nurs. 2014;Suppl:S15-S20. PMID: 25039458. https://doi.org/10.12968/bjcn.2014.19.sup7.s15

7. Aslakson RA, Reinke LF, Cox C, Kross EK, Benzo RP, Curtis JR. Developing a Research Agenda for Integrating Palliative Care into Critical Care and Pulmonary Practice To Improve Patient and Family Outcomes. J Palliat Med. 2017;20(4):329-343. PMID: 28379812. PMCID: PMC5385425. https://doi.org/10.1089/jpm.2016.0567

8. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med. 2010;363(8):733-742. PMID: 20818875. https://doi.org/10.1056/nejmoa1000678

9. Ferrell BR, Temel JS, Temin S, et al. Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(1):96-112. PMID: 28034065. https://doi.org/10.1200/jco.2016.70.1474

10. Kaasa S, Loge JH, Aapro M, et al. Integration of oncology and palliative care: a Lancet Oncology Commission. Lancet Oncol. 2018;19(11):e588-e653. PMID: 30344075. https://doi.org/10.1016/s1470-2045(18)30415-7